Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T17:22:10.093Z.
Calculation as of: 2026-10-06T17:22:10.093Z.
Quote observation: 2026-10-06T17:16:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 581b2fbaae035830ca35d06372124b56c7048e0f0ab23ef832a371d1053372ba
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$13.51M
EV/Sales Ratio
63.82x
TTM Avg
135.82x
3Y Avg
650.44x
5Y Avg
556.96x
Market Cap
$13.56M
EV/Sales Ratio
0.52x
TTM Avg
1.89x
3Y Avg
1.89x
5Y Avg
1.89x
Market Cap
$13.69M
EV/Sales Ratio
44.83x
TTM Avg
16.53x
3Y Avg
4.93x
5Y Avg
3.45x
Market Cap
$13.76M
EV/Sales Ratio
9.58x
TTM Avg
6.53x
3Y Avg
5.18x
5Y Avg
1267.27x
Market Cap
$12.82M
EV/Sales Ratio
0.93x
TTM Avg
1.49x
3Y Avg
1.84x
5Y Avg
2.28x
Market Cap
$12.70M
EV/Sales Ratio
N/A
TTM Avg
47034.37x
3Y Avg
20535.90x
5Y Avg
21687.86x
Market Cap
$13.98M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IN8bio, Inc. (INAB) | $13.33M | N/A | N/A | N/A | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.51M | 63.82x | 135.82x | 650.44x | 556.96x |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.56M | 0.52x | 1.89x | 1.89x | 1.89x |
| Vyome Holdings, Inc. (HIND)vs › | $13.69M | 44.83x | 16.53x | 4.93x | 3.45x |
| Sintx Technologies, Inc. (SINT)vs › | $13.76M | 9.58x | 6.53x | 5.18x | 1267.27x |
| Passage Bio, Inc. (PASG)vs › | $12.88M | N/A | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.82M | 0.93x | 1.49x | 1.84x | 2.28x |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.70M | N/A | 47034.37x | 20535.90x | 21687.86x |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $13.98M | N/A | N/A | N/A | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.03M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
